Covaris is dedicated to accelerating discoveries in life sciences and bioanalysis by developing cutting-edge sample preparation tools. AFA-energetics® is the gold standard for shearing DNA and RNA for Next Generation Sequencing (NGS) and is setting new standards in FFPE-related DNA/RNA/protein extraction, cfDNA extraction, epigenomics, proteomics, cell lysis and more. Covaris Adaptive Focused Acoustics® (AFA®) technology is the only high-throughput (>96 samples) chromatin sample preparation platform available for a wide range of chromatin-based applications. Some additional applications include Methyl-Seq, Protein-DNA interaction studies, meDIP-Seq, ChIP-Seq and more.
At Diagenode, our goal is to build products and offer services with pride and the highest level of performance. Based in Liege, Belgium and NJ, USA, our team of epigenetics experts have developed innovative Bioruptor® shearing and unique IP-Star® automation instruments, reagent kits, and highly validated antibodies to streamline DNA methylation, and ChIP-seq workflows. The company's latest innovations include the Megaruptor shearing system for long fragment generation in sequencing and epigenetics assay services.
Resverlogix Corp. (TSX:RVX), is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. Resverlogix is a pioneer in the landscape of epigenetics. Apabetalone is the world leader in a new class of drugs designed to regulate gene expression through the inhibition of bromodomain and extraterminal domain (BET) proteins. Through this mechanism, we believe we can improve the lives of our patients by restoring biological functions – altered by serious illnesses such as cardiovascular disease – to a healthy state. The prevalence of BET proteins in the human body allows apabetalone to simultaneously target multiple disease-causing biological processes – leading a new paradigm shift in the treatment of chronic disease. Apabetalone is currently being evaluated in a Phase 3 clinical trial – BETonMACE – for the treatment of high-risk cardiovascular disease patients, who also have type 2 diabetes mellitus and low levels of high-density lipoprotein.